SCHEMBL6841219

SCHEMBL6841219

CCOC(=O)c1cccc(CCc2cncc3ccccc23)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.54
CYP4A11 Q02928 1/20 0.54
CDC25B P30305 2/20 0.48
MAPT P10636 7/20 0.45
SMN1; SMN2 Q16637 5/20 0.44
ALDH1A1 P00352 4/20 0.44
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
ALOX15 P16050 1/20 0.44
CDC25A P30304 1/20 0.43
CDC25C P30307 1/20 0.43
TP53 P04637 1/20 0.43
EGFR P00533 1/20 0.43
KDR P35968 1/20 0.43
MEP1B Q16820 1/20 0.43
KDM4E B2RXH2 4/20 0.43
KMT2A Q03164 4/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NAMPT P43490 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6846819 0.83 SLC16A3 (0.53) SMN1; SMN2HTT
SCHEMBL9454406 0.79 CYP4F2 (0.73) CYP4F2CYP4A11MAPTSMN1; SMN2ALDH1A1
SCHEMBL6841295 0.77 ADRB2 (0.47) MAPTSMN1; SMN2ALDH1A1KDM4EKMT2A
SCHEMBL6841197 0.76 SMN1; SMN2 (0.44) MAPTSMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL6841307 0.76 MMP9 (0.44) SMN1; SMN2ALDH1A1RAB9ANPC1KDR
SCHEMBL10731156 0.75 CYP4F2 (0.58) CYP4F2CYP4A11MAPTSMN1; SMN2ALDH1A1
SCHEMBL12035616 0.74 CYP4F2 (0.75) CYP4F2CYP4A11MAPTSMN1; SMN2ALDH1A1
SCHEMBL6841287 0.74 CDC25B (0.47) CDC25BMAPTSMN1; SMN2NPC1ALOX15
SCHEMBL6846571 0.74 CDC25B (0.47) CDC25BMAPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL10895485 0.74 EGFR (0.57) CDC25BMAPTSMN1; SMN2ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 US disclosed
US-6635641-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS, INC. 2003-10-21 US disclosed
EP-1252146-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 EP disclosed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 US disclosed
WO-2001053274-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA CYP4F2 4688/4885CYP4A11 3731/4885CDC25B 187/4885
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA CYP4F2 4688/4885CYP4A11 3731/4885CDC25B 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.